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Abstract 
Veterinary vaccines contribute to improved human and animal health and welfare by preventing diseases and deaths caused by a 
wide range of infectious agents. However, testing necessary to ensure vaccine effectiveness and safety can involve large numbers
of animals and significant pain and distress. NICEATM and ICCVAM convened an international workshop to review the state of 
the science of human and veterinary vaccine potency and safety testing methods and to identify opportunities to advance new and
improved methods that can further reduce, refine, and replace animal use. This workshop report is the fourth in a series of six,
and addresses methods and strategies for veterinary vaccine potency testing that can avoid or lessen pain and distress, improve
animal welfare, and reduce animal use. Vaccine potency tests considered to have the highest priority for further reduction and 
refinement were those that require an infectious agent challenge test or an in vivo toxin neutralization test, those that require large 
numbers of animals, and those that require the use of infectious agents hazardous to laboratory workers and/or animals. Vaccines
identified as high priorities for improved alternative test methods were rabies, Clostridium spp., Leptospira spp., foreign animal 
diseases (e.g., foot and mouth disease), and poultry and fish vaccines. The workshop recommended priority research, 
development, and validation activities to address critical knowledge and data gaps, including opportunities to apply new science
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and technology. Recommendations to support more humane animal use included development and use of humane endpoints for 
all challenge tests, development of serologic assays to replace challenge tests, and development of in vitro toxin neutralization 
tests to replace in vivo TNTs. Workshop participants recommended approaches to reduce the number of animals required for 
potency testing, and recommended enhanced international harmonization and cooperation, and closer collaborations between 
human and veterinary researchers to expedite progress in the development and application of alternative methods. 
Implementation of the workshop recommendations is expected to advance new methods for veterinary vaccine potency testing 
that will benefit animal welfare and reduce animal use while ensuring continued protection of human and animal health. 
© 2011 Published by Elsevier Ltd. Selection and/or peer-review under responsibility of the National Toxicology Program 
Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM) 
Keywords: veterinary vaccines; vaccine potency testing; vaccine safety testing; refinement alternatives; reduction alternatives; ICCVAM 
1. Introduction 
Veterinary vaccines contribute to improved human and animal health and welfare by preventing infection and 
controlling infectious agents that can cause disease and death. However, the testing necessary to ensure vaccine 
effectiveness and safety can involve large numbers of animals and significant pain and distress. In the United States, 
the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) and the National 
Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM) 
promote the scientific validation and regulatory acceptance of test methods that accurately assess the safety of 
chemicals and products while reducing, refining (less or no pain and distress), and replacing animal use. 
Accordingly, NICEATM and ICCVAM recently identified vaccine potency and safety testing as one of their four 
highest priorities [1].  
ICCVAM is an interagency committee of Federal agencies that is charged by law with evaluating new, revised, 
and alternative test methods with regulatory applicability. ICCVAM members represent 15 U.S. Federal regulatory 
and research agencies that require, use, generate, or disseminate safety testing data. These include the U.S. 
Department of Agriculture (USDA), which regulates veterinary vaccines, and the U.S. Food and Drug 
Administration (FDA), which regulates human vaccines. ICCVAM is a permanent interagency committee of the 
National Institute of Environmental Health Sciences (NIEHS) under NICEATM. NICEATM administers ICCVAM, 
provides scientific and operational support for ICCVAM-related activities, and conducts international validation 
studies on promising new safety testing methods. NICEATM and ICCVAM serve a critical public health role in 
translating research advances from the bench into standardized safety testing methods that can be used in regulatory 
practice to prevent disease and injury. 
To promote and advance the development and use of scientifically valid alternative methods for human and 
veterinary vaccine testing, NICEATM and ICCVAM organized the International Workshop on Alternative Methods 
to Reduce, Refine, and Replace the Use of Animals in Vaccine Potency and Safety Testing: State of the Science and 
Future Directions. The workshop was held at the National Institutes of Health in Bethesda, Maryland, on 
September 14–16, 2010. It was organized in conjunction with the European Centre for the Validation of Alternative 
Methods (ECVAM; European Commission, Joint Research Centre, IHCP), the Japanese Center for the Validation of 
Alternative Methods (JaCVAM), and Health Canada. 
The workshop addressed the state of the science of human and veterinary vaccine potency and safety testing. 
Participants developed recommendations for future progress in three major areas: (1) in vitro replacement methods 
for potency testing; (2) reduction and refinement methods for potency testing; and (3) reduction, refinement, and 
replacement methods for vaccine safety testing [2]. Workshop reports for each of the three topics for human 
vaccines and for each of the three topics for veterinary vaccines were prepared based on the contributions of invited 
experts and the general public during the various plenary presentations and dedicated breakout group sessions [3, 4, 
5, 6, 7, 8]. This report addresses methods and strategies for the reduction and refinement of animal use for potency 
testing of veterinary vaccines.
Three major strategies for reduction and refinement are discussed. The first is the application of earlier humane 
endpoints to reduce the duration and severity of pain and distress that can occur during challenge testing. Challenge 
© 201  Published by Elsevier Ltd. Sele ti  / r r-review under responsibility of the National 
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testing is conducted to determine the amount of vaccine required to protect animals from infection with live agents, 
and inadequately protected and control animals often develop clinical disease or die. The second strategy is the 
development and use of serological methods that can eliminate the need for challenge testing. In serological 
methods, the amount of protective antibody produced is measured and serves as an indicator of vaccine potency. 
The final strategy involves the application of methods and approaches that may reduce the number of animals in 
each test. 
2. Goals and organization of the workshop 
The goals of the international workshop were to: (1) identify and promote the implementation of currently 
available and accepted alternative methods that can reduce, refine, and replace the use of animals in human and 
veterinary vaccine potency and safety testing; (2) review the state of the science of alternative methods and identify 
knowledge and data gaps that need to be addressed; and (3) identify and prioritize research, development, and 
validation efforts needed to address these gaps in order to advance alternative methods that will also ensure 
continued protection of human and animal health. 
The workshop was organized with four plenary sessions and three breakout group sessions. In the breakout 
sessions, workshop participants: 
x Identified criteria to prioritize vaccine potency and safety tests for future alternative test method development, 
and identified high priorities using these criteria  
x Reviewed the current state of the science of alternative methods and discussed ways to promote the 
implementation of available methods 
x Identified knowledge and data gaps that need to be addressed 
x Identified and prioritized research, development, and validation efforts needed to address these gaps in order to 
advance alternative methods while ensuring continued protection of human and animal health 
The workshop opened with a plenary session in which expert scientists and regulatory authorities from the United 
States, Europe, Japan, and Canada outlined the importance of vaccines to human and animal health [9, 10] and 
described national and international regulatory testing requirements for human and veterinary vaccines [2, 11, 12, 
13, 14, 15, 16]. Authorities emphasized that, following the approval of a vaccine, testing is then required to ensure 
that each subsequent production lot is safe and sufficiently potent to generate a protective immune response in 
people or animals [11, 12]. 
The second plenary session addressed methods that have been accepted and methods that are in development that 
do not require the use of animals for assessing the potency of vaccines [17, 18, 19, 20]. This was followed by 
breakout sessions to discuss the state of the science and recommendations for future progress for in vitro potency 
tests for human and veterinary vaccines. Workshop recommendations to advance the use and development of 
alternative methods that can replace animals for the potency testing of human [3] and veterinary vaccines [4] are 
available elsewhere in these proceedings. 
The third plenary session addressed (1) potency testing methods that refine procedures to avoid or lessen pain and 
distress by incorporating earlier humane endpoints or by using antibody quantification tests instead of challenge 
tests and (2) methods and approaches that reduce the number of animals required for each test [21, 22, 23, 24, 25, 
26, 27]. Breakout groups then discussed the state of the science and developed recommendations for future progress. 
Workshop recommendations to advance the use and development of alternative methods that can reduce and refine 
animal use for potency testing of veterinary vaccines are provided in this paper. Recommendations for human 
vaccines are available elsewhere in these proceedings [5]. 
The final plenary session addressed methods and approaches for reducing, refining, and replacing animal use to 
assess the safety of serial production lots of human and veterinary vaccines [11, 28, 29, 30]. Breakout groups then 
discussed the state of the science and developed recommendations for advancing alternative methods for vaccine 
safety testing. Workshop recommendations to advance the use and development of alternative methods for safety 
testing of veterinary vaccines [8] and human vaccines [7] are available in these proceedings. 
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3. Requirements for veterinary vaccine potency testing
Strict regulations and guidelines are designed to ensure that each veterinary vaccine product released for sale is 
pure, safe, potent, and effective [31]. An estimated 18,000 serials (batches) of veterinary vaccines are released 
annually in the United States for approximately 2000 different products that protect animals from 213 different 
animal diseases [12]. Given that many of the inactivated vaccines still require animals for potency testing, 
significant numbers of animals are necessary.  
Veterinary vaccines contribute to the health and well being of animals and people. In addition to controlling and 
preventing diseases of companion and domestic animals, vaccines help ensure a safe and efficient global food 
supply. They reduce the transmission of zoonotic and food borne infections from animals to people. Vaccines also 
reduce the need for low-level antibiotics to control some diseases in food animals. 
 Due to the number of animals used annually for the release of veterinary vaccines, global regulatory agencies 
actively encourage the evaluation, development, and implementation of novel approaches that reduce, refine, and 
replace (3Rs) the use of animals in vaccine safety and potency product release testing [12, 14, 22]. 
Current veterinary vaccines consist of modified live (attenuated) viruses and bacteria, inactivated (killed) viruses 
and bacteria, toxoid or bacterin toxoids, peptide and subunit vaccines, and genetically engineered products. The 
general types of potency tests employed by vaccine manufacturers include (1) titration of live organisms (in vitro
assays, but occasionally in vivo), (2) in vitro assays such as enzyme-linked immunosorbent assays (ELISAs) or other 
antigen quantification methods, (3) serology methods to quantify protective antibody or antitoxin, and (4) 
vaccination-challenge in vivo methods using either the host animal (e.g., fish, poultry) or laboratory animals (e.g., 
hamsters, mice) [17]. Reduction and refinement procedures are especially applicable to serological and vaccination–
challenge potency testing methods, both of which require the use of animals. 
4. Prioritizing vaccine potency tests for future refinement and reduction efforts 
Potency testing for many veterinary vaccines still requires the use of animals for challenge tests, serological 
assays, and some toxin neutralization tests (TNTs). For these veterinary vaccine testing situations, workshop 
participants recommended that the following should have the highest priority for further development and validation 
activities relevant to reduction and refinement of animal use: 
x Potency testing that involves significant animal pain and distress, such as challenge testing and in vivo TNTs 
x Potency testing that uses large numbers of animals, based on both the number of animals used per potency test 
and the number of serials tested annually 
x Potency testing that requires live viruses and bacteria that are highly contagious and/or hazardous to laboratory 
workers, livestock, pets, and wildlife, including foreign animal diseases in countries that are free of such diseases 
(e.g., foot and mouth disease and bluetongue disease) 
x Potency testing for which there are ongoing alternative development and validation activities  
x Potency tests for new vaccines that are currently undergoing prelicensing development and evaluation 
Based on these criteria, the highest priorities recommended for further development of alternative vaccine 
potency test methods include the following: 
x Rabies vaccines
x Leptospira spp. bacterial vaccines 
x Clostridium spp. bacterial vaccines for which an in vivo TNT is still used 
x Any potency test that still requires a challenge test  
x Potency tests that still require the use of foreign animal diseases, especially foot and mouth disease and 
bluetongue disease 
x Poultry vaccines 
x Fish vaccines 
x New vaccines 
Rabies, Clostridium spp., and Leptospira spp. vaccines, as well as fish and poultry vaccines, were identified as 
the highest priorities because these potency tests require large numbers of animals, and most involve either 
challenge or in vivo toxin neutralization testing that can involve significant animal pain and distress. Workshop 
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participants also recommended that manufacturers seek and consider alternative assays during the development 
phase for new vaccines that could then be used for subsequent lot release potency and safety testing. 
Many of these priority vaccines already have alternative potency test assays in various stages of development and 
validation and published guidances for some alternative tests are available in some countries and regions. For 
example, the Council of Europe publishes monographs in the European Pharmacopoeia, and the U.S. Department of 
Agriculture publishes regulations according to Title 9 of the U.S. Code of Federal Regulations. The USDA also 
publishes supplemental assay methods (SAMs) that include more detailed test method protocols. Vaccine 
manufacturers can use this guidance to conduct product-specific validation for each vaccine testing procedure and 
submit it to the appropriate regulatory authority for approval. 
5. Veterinary vaccine potency testing: using humane endpoints to refine animal use
5.1. State of the science 
Many veterinary vaccines still require the use of animals for challenge tests to quantify and demonstrate potency 
before serial release. Although death is not a required endpoint for veterinary vaccines, death often occurs when 
there is rapid progression from a clinically normal to an overtly ill condition. Moribund condition currently serves as 
the default endpoint for early termination of in vivo vaccine potency tests [32]. Ideally, earlier euthanasia of 
individual animals should be based upon standardized, earlier, and more humane endpoints.  
Humane endpoints are criteria that can be used as the basis for ending a test or research procedure earlier in order 
to avoid further pain and distress. Ideally, humane endpoints can be used as criteria to end a procedure before the 
onset of animal pain and distress [33, 34, 35]. However, the use of earlier, more humane endpoints must be capable 
of achieving the specific testing or research objectives. The use of available, scientifically valid humane endpoints 
wherever possible is also a fundamental principle of the U.S. Public Health Service Policy on Humane Care and Use 
of Laboratory Animals [36], as well as existing statutory requirements in the United States [37] and the European 
Union (former Directive 86/609 and recently issued Directive 2010/63) [38, 39]. 
Specific policies have been adopted that incorporate the use humane endpoints during vaccine potency testing 
procedures [33, 40, 41]. The use of humane endpoints is also reflected in regulatory guidance documents and/or 
legislation (e.g., U.S. Code of Federal Regulations, European Directorate for the Quality of Medicines (EDQM), and 
associated European Pharmacopoeia) of relevant agencies in numerous regions and countries worldwide [33. 34, 35, 
40, 41, 42] (Table 1). For example, the Center for Veterinary Biologics (CVB) Notice No. 04-09, issued in 2004 
[43], provides for humane endpoints by stating that moribund animals may be humanely euthanized and considered 
as deaths provided that the details for humane endpoints are stated in the outline of production for the specific 
vaccine.
Several types of observations and measurements may serve as humane endpoints:
x Observation of clinical signs, including behavioral changes 
x Measurement of changes in physiological parameters such as body temperature, body weight, heart rate, and 
respiratory rate 
x Measurement of changes in serum or blood biomarkers, such as specific clinical chemistry or hematology 
parameters [25, 35, 42]  
Successful implementation of clinical signs as humane endpoints requires comprehensive training of animal care 
staff [35, 46].  
For some existing vaccines that require a challenge test, the procedure has been refined to reduce animal pain and 
distress by incorporating earlier and more humane endpoints. For example, earlier humane endpoints for veterinary 
rabies vaccines have been approved and adopted for use in the United States and internationally, thereby reducing 
both the duration and severity of pain and distress in test animals [47, 48, 54] (Table 2). Humane endpoints of 
paresis, paralysis, and/or convulsions were determined to sufficiently predict rabies infection and indicate that the 
animal would not recover [49]. Similar humane endpoints are in place for human rabies vaccine potency testing [19, 
50].  
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Table 1. Regulations, policies, and guidance for the use of humane endpoints 
Organization Citation Text 
USDA 9 CFR 117.4(e) 
(1998) [40] 
“Test animals that show clinical signs of illness that are due to test may be treated or humanely 
destroyed if the illness has progressed to a point ….when death is certain to occur without therapeutic 
intervention.”
USDA CVB Notice 
No. 04-09 
(2004) [43] 
Sets the provision for humane endpoints by stating that moribund animals may be humanely euthanized 
and considered as deaths, provided the details for humane endpoints are stated in the Outline of 
Production for the specific vaccine. 
CCAC CCAC
Guidelines
(1998) [44] 
“… investigators should eliminate, mitigate, or minimize potential pain and distress whenever feasible 
and consistent with good scientific practice.” 
OLAW, NIH Public Health 
Service Policy 
on Humane 
Care and Use of 
Laboratory 
Animals (2002) 
[36] 
“… discomfort to animals will be limited to that which is unavoidable for the conduct of scientifically 
valuable research, and that unrelieved pain and distress will only continue for the duration necessary to 
accomplish the scientific objectives. Animals that would otherwise suffer severe or chronic pain and 
distress that cannot be relieved should be painlessly killed at the end of the procedure, or if appropriate, 
during the procedure” 
a) Council of 
Europe 
b) Council of 
Europe 
(2011)  
a) Introduction 
to the European 
Pharmacopoeia 
since 3rd edition 
(1998) 
b) Vaccines for 
veterinary use 
(Ph. Eur. 
Monograph 
062) 
European
Pharmacopoeia 
7th Edition [41] 
a) General statement on commitment to "alternative procedures"
b) “… if it is indicated that an animal is considered to be positive, infected etc. when typical clinical 
signs occur then as soon as it is clear that result will not be affected the animal in question shall either be 
euthanised or given suitable treatment to prevent unnecessary suffering.” 
European
Union 2010 
Directive
2010/63/EU 
[39] 
“The methods selected should avoid, as far as possible, death as an end-point due to the severe suffering 
experienced during the period before death. Where possible, it should be substituted by more humane 
end- points using clinical signs that determine the impending death, thereby allowing the animal to be 
killed without any further suffering.”
ICLAS Demers et al. 
2006 [45] 
“Death or severe pain and distress should be avoided as end points. The earliest possible end point 
should be used that is consistent with the scientific objectives. Studies should be designed to minimize 
any pain or distress likely to be experienced by the animals, while meeting the scientific objectives. The 
duration of studies involving pain and distress should be kept to a minimum. Pilot studies should be 
encouraged as a means of determining morbidity, time course of effects, and frequency of observations 
required to set an earlier end point …. Animals should be monitored by means of behavioral, 
physiological, and/or clinical signs at an appropriate frequency to permit timely termination of the 
experiment once the end point has been reached.” 
USDA – United States Department of Agriculture 
CFR – Code of Federal Regulations 
CVB – Center for Veterinary Biologics 
CCAC – Canadian Council on Animal Care 
OLAW, NIH – Office of Laboratory Animal Welfare, National Institutes of Health 
ICLAS – International Council for Laboratory Animal Science 
Earlier humane endpoints for other vaccine-challenge tests have also been described and endorsed by regulatory 
authorities. For example, post-challenge earlier humane endpoints for the swine vaccine for Erysipelas
rhusiopathiae include pathognomonic, diamond-shaped erythematous skin lesions, elevated temperature, and 
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arthritis [22, 51, 52]. For challenge testing of chicken fowlpox vaccine, earlier humane endpoints include pox 
lesions, warty eruptions, and scabs on the comb and wattles [22, 53] (Table 2).
Table 2. Veterinary vaccine potency assays that incorporate earlier humane endpoints for challenge testing 
Vaccine Product 
(Disease) Humane Endpoints References
Traditional Test Procedure for Which 
the Alternative Method is Applicable 
Inactivated
rabies virus vaccine 
(Lyssavirus rabies)
Convulsions, paralysis, 
paresisa,b
Cussler et al. 1998 [49]; Bruckner 
et al. 2003 [54]; 
Wunderli et al. 2006 [55]; 
9 CFR 117.4e [40];  
9 CFR 113.209;  
USDA SAM 308 (2007) [47]; 
Ph. Eur. Monograph 451 [48] 
Moribund condition or death previously 
used as study endpoints 
Inactivated swine 
erysipelas vaccine 
(Erysipelothrix
rhusiopathiae)
Pathognomonic, diamond-
shaped erythematous skin 
lesions, elevated 
temperature, arthritisa
Johannes et al. 2003 [52]; Srinivas 
2011 [22]; 9 CFR 113.67 [56] 
Moribund condition or death previously 
used as study endpoints  
Fowlpox virus vaccine Pox lesions, warty 
eruptions/scabs on combs 
and wattlesa
Srinivas 2011 [22];  
9 CFR 113.326 [57] 
Moribund condition or death previously 
used as study endpoints 
a Accepted by U.S. regulatory authorities.
b Published in the European Pharmacopoeia.
However, humane endpoints for many commonly used veterinary vaccines, including some Clostridium and 
Leptospira spp. vaccines, have not been identified. The potency test for many Clostridium spp. vaccines produced in 
the United States consists of vaccination-challenge in laboratory animals or, more commonly, vaccination of 
laboratory animals followed by titration of serum in a toxin–antitoxin neutralization test using mice. Although the 
potency tests for all of these Clostridium spp. disease vaccines incorporate humane euthanasia as described in 
9 CFR 117.4 [40], earlier more humane endpoints have yet to be developed for challenge tests and toxin–antitoxin 
neutralization tests. Applicable examples include potency testing of Clostridium chauvoei [58] and Clostridium 
haemolyticum [59] using vaccination–challenge testing in guinea pigs, and potency testing of Clostridium botulinum
using a vaccination–challenge test in mink [60]. For Clostridium perfringens Type C [61], Clostridium perfringens
Type D [62], Clostridium novyi Type B [63], and Clostridium sordellii [64], rabbits are vaccinated, and serum is 
titrated using a toxin–antitoxin neutralization test in mice.  
For many Leptospira spp. vaccines, hamsters are used to assess potency by vaccination–challenge methods [65, 
66]. Humane endpoints have yet to be defined for these vaccines, including Leptospira interrogans serovars; 
pomona [67], canicola [68], icterohaemorrhagiae [69], and grippotyphosa [70]. Animals that become moribund are 
humanely euthanized as outlined in 9 CFR 117.4 [40].
In summary, progress has been made in identifying earlier humane endpoints for some vaccines that still involve 
challenge testing with live agents. However, workshop participants concluded that it is imperative for concerted 
efforts to be made to identify humane endpoints for all vaccines that still require challenge testing and for which 
there are no earlier humane endpoints, especially for Clostridium and Leptospira spp. vaccines. These efforts should 
include systematic collection and evaluation of data to identify appropriate clinical or other objective parameters 
that are predictive of current test endpoints, and that can then be used as earlier humane endpoints to reduce pain 
and distress in test animals. 
5.2. Knowledge gaps and priority research, development, and validation activities 
Workshop participants agreed that earlier humane endpoints should be investigated for use for all challenge 
testing situations. Key priorities included the need for a thorough understanding of disease progression during a 
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challenge test, including the identification of earlier humane endpoints through routine systematic collection and 
evaluation of all clinical signs.  
Although humane endpoints have been identified and incorporated into regulatory guidelines for some products, 
many potency tests still use procedures in which the endpoint is moribund condition rather than early clinical signs 
consistent with disease pathogenesis (9 CFR 117.4) [40]. Identifying earlier endpoints for rabies vaccine testing than 
the current obvious clinical signs of paresis, paralysis, and convulsions is also desirable. However, this will require 
better understanding of measurable and/or other subtle observable changes that precede and predict these more 
obvious clinical signs. 
Workshop participants identified key knowledge gaps that need to be addressed to advance the validation and 
implementation of humane endpoints: 
x Improved understanding of measurable and/or observable changes that lead to overt clinical signs and moribund 
condition 
x Improved understanding and investigation of potentially useful objective quantitative endpoints 
x Understanding of the causes that lead to inconsistent patterns of moribund condition 
x Identification of earlier endpoints for diseases with rapid progression from normal clinical state to death 
x Confirmation that the use of humane endpoints for specific challenge tests do not lead to a higher rate of 
inconclusive test outcomes 
x Increased availability of data collected to identify humane endpoints, and public access to such data 
x Improved understanding of early clinical signs in fish that are predictive of eventual moribund condition or death 
Workshop participants recommended increasing awareness within the vaccine industry about the concept of 
humane endpoints and providing greater access across the industry to all relevant information about useful endpoints 
as well as the process for identifying humane endpoints. An existing example that could be distributed is a video 
demonstrating the assessment and use of paresis, paralysis, and convulsions as humane endpoints for rabies vaccines 
[54].  
Workshop participants recommended the following priority activities to advance the validation and 
implementation of humane endpoints: 
x Improved guidance on and training in recognition of early clinical signs  
x Identification of earlier humane endpoints for all vaccine potency challenge testing, with a priority for Leptospira 
spp. challenge testing  
x Identification of earlier humane endpoints for control groups in challenge testing, in which clinical signs may be 
earlier and more overt in vaccinates that have partial but inadequate protection
x Systematic collection and evaluation of clinical and other objective data during prelicensing efficacy tests, which 
may identify earlier humane endpoints applicable for use in subsequent lot release testing  
x Enhanced, more innovative methods for observing animals  
To better understand disease progression during challenge testing and to expedite future data collection, 
workshop participants recommended that clinical data for control animals should be initially analyzed to identify 
earlier clinical endpoints. Control data should also be evaluated to determine if there is a threshold percentage of 
controls that exhibit the specific humane endpoints that is sufficiently predictive that the remainder of the controls 
will succumb. If so, this threshold could be used as the basis for early termination of all remaining control animals. 
Workshop participants suggested that earlier humane endpoints for control animals might be especially applicable to 
poultry and fish vaccines. Clinical observations from prelicensing vaccination efficacy studies should be maintained, 
summarized, and reviewed to identify earlier humane endpoints for post-licensing serial release potency testing. 
Humane endpoints are more likely to be identified for challenge testing in which animals take longer to develop and 
succumb to disease (e.g., Leptospira spp.).
Workshop participants recommended further research to develop enhanced, innovative methods for observing 
animals more frequently to detect the onset of clinical signs identified as humane endpoints. Adaptation of video or 
real-time computer monitoring techniques may be useful for this purpose. Workshop participants also recommended 
that the frequency of animal observations should be increased to that necessary to minimize spontaneous deaths, 
with observations made at least twice daily. 
Finally, workshop participants recommended that broader implementation of humane endpoints can be supported 
by (1) disseminating information on the clinical signs associated with each disease and (2) sharing information 
between manufacturers and regulators regarding valid and acceptable humane endpoints. Manufacturers should be 
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encouraged to identify and implement humane endpoints for all challenge testing. Nevertheless, the need for more 
frequent observation of animals and advanced clinical surveillance and monitoring equipment could add additional 
expense. Manufacturers will also need to work with appropriate regulatory authorities to modify documentation 
such as Outlines of Production in accordance with established procedures.
6. Veterinary vaccine potency testing: using serological methods to refine animal use 
6.1. State of the science 
For some vaccines, the traditional vaccine potency challenge test has been replaced by a serological method. 
Serological methods measure the amount of protective antibody produced in vaccinated animals, which is compared 
to the reference antibody value known to provide protection in the challenge test. A validated laboratory assay 
quantifies the amount of protective antibody produced in response to the vaccination dose. Serological testing 
thereby provides for significant refinement compared to challenge testing by avoiding the pain and distress resulting 
from infections in unprotected vaccinates and control animals.  
Serological methods have been developed and validated for many veterinary vaccines, such as inactivated 
Erysipelothrix rhusiopathiae vaccine [71] (Table 3). However, for some vaccines, the serum collected from 
vaccinated animals may still require additional animals in a test to determine the presence of protective antibodies to 
toxin. This test, known as the in vivo Toxin Neutralization Test (TNT), involves combining the protective antibody 
collected form vaccinated animals with known amounts of toxin produced by the causative agent (e.g., Clostridium 
spp. vaccines). This mixture is administered to laboratory animals to assess whether the level of protective antibody 
fully neutralizes the toxin. If sufficient protective antibody is present to fully neutralize the toxin, the test animals 
are not exposed to any free toxin and survive. However, if there is residual free toxin, the test animals develop 
clinical signs or die. Validated in vitro methods to quantify antibodies for some toxins are now available. Examples 
include an indirect ELISA for inactivated erysipelas vaccines [71], an indirect ELISA [72] and a toxin-binding 
inhibition (ToBI) test for tetanus [73], and the in vitro RFFIT (rapid fluorescent focus inhibition test) for rabies 
vaccines (Table 3). Toxin neutralization tests using cell cultures are available for potency testing for Clostridium 
perfringens C/D [74], Clostridium septicum [75], and Clostridium novyi (Type B) vaccines [76, 77] (Table 3).
Serological methods for potency testing of Leptospira spp. vaccines are available for dogs [78] and cattle [79] 
(Table 3). Canine leptospirosis vaccine (inactivated, nonadjuvanted) is a preparation of inactivated whole organisms 
and/or antigenic extract(s) of one or more Leptospira interrogans serovars (e.g., canicola, icterohaemorrhagiae, or 
any other epidemiologically appropriate serovar). Bovine leptospirosis vaccine (inactivated) is a preparation of 
inactivated whole organisms and/or antigenic extract(s) of one or more suitable strains of L. borgpetersenii (serovar 
hardjo) or L. interrogans (multiple serovars). For each of the serovars for which protection is claimed, the antibody 
response is measured in vaccinated, disease-free guinea pigs. Serum is tested using any suitable validated method, 
such as a micro-agglutination test, to measure the antibodies in each sample [79] (Table 3).
6.2. Knowledge gaps and priority research, development, and validation activities 
Workshop participants identified knowledge gaps and research necessary to develop and validate serological 
methods that could be used instead of challenge tests and in vivo TNT: 
x Identification of functional protective antigens and corresponding antibodies 
x Availability of reagents and standards to conduct specific antibody quantification assays and stability testing 
procedures
x Improved substrates to detect enzymatic activity of toxins using specific cell lines 
x Research into new immune-based methodologies  
The functional antigen and protective antibody must be identified in order to develop and standardize an in vitro
assay to quantify the antibody response. The goal is to identify a serological threshold of protective antibody above 
which the vaccine is considered adequately potent. The threshold should correlate with in vivo protection. 
Serological testing usually involves a relative potency test in which the antibody response in the test serial is 
compared to that of a standard reference. The requirement for a standard reference varies by authority and the 
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specific approved license. A number of issues associated with a standard reference must be addressed, including 
preparation, quantification, validation, stability, and requalification. Qualification of the standard reference requires 
an in vivo host animal immunogenicity test or preparation of a serial adjusted to be equivalent to the reference that is 
then used in the host animal efficacy study. Typically, the frozen reference can be stored for up to five years. Under 
refrigeration conditions, the reference can be stored for up to two years [97]. However, assays must be developed, 
validated, and implemented that can adequately monitor the stability of the reference during storage. 
Table 3. Examples of veterinary vaccine potency assays that incorporate immunization and in vitro antibody 
quantification (serology) alternative methods 
Vaccine Product 
(Disease) 
3R Alternative References For Alternative Methods 
Traditional Test 
Procedure for Which 
the Alternative Method 
is Applicable 
References For 
Traditional Methods 
Inactivated rabies 
vaccine
(Lyssavirus rabies)
Immunization (mice) and 
serologya: In vitro RFFIT 
(rapid fluorescent focus 
inhibition test) 
Kramer et al 2010 [80]; 
Kramer et al. 2009 [81]; 
Cliquet et al. 1998 [82]; 
Nagarajan et al. 2006 [83];
USDA SAM 315 (1986) 
[84]; Ph. Eur. Monograph 
451 [85] 
Immunization challenge 
in mice (intracerebral)b
9 CFR 113.209 [47] 
Inactivated swine 
erysipelas vaccine 
(Erysipelothrix
rhusiopathiae)
Immunization (mice) and 
serology: In vitro antibody 
quantificationa,c– ELISA 
Rosskopf-Streicher et al. 
2001 [86]; Beckmann and 
Cussler 1994 [87]; 
USDA SAM 613 (2009) 
[88]; 
Ph. Eur. Monograph 064 
[71] 
Mouse lethal challenge 
test
9 CFR 113.119; USDA 
SAM 611 (2008) [89] 
Clostridium novyi
(Type B); Bovine 
(Black disease) 
Immunization (rabbits) and 
serologya d: In vitro
immunochemical method or 
neutralization in cell cultures 
(specific details not provided 
in Ph. Eur. monograph) 
Hendriksen et al. 1998 
[90]; EDQM 1997, 2007 
[91]; Ph. Eur. Monograph 
362 [76]  
Rabbit
immunization/mouse 
toxin neutralization test 
9 CFR 113.108; USDA 
SAM 207 (2007) [63] 
Clostridium septicum;
Bovine
(malignant edema) 
Immunization (rabbits) and 
serologya d: In vitro 
immunochemical method or 
neutralization in cell cultures 
(specific details not provided 
in Ph. Eur. monograph) 
Hendriksen et al. 1998 
[90]; EDQM 1997, 2007 
[91]; Ph. Eur. Monograph 
364 [75] 
Rabbit
immunization/mouse 
toxin neutralization test 
-
Clostridium
perfringens C/D;
Bovine
(Enterotoxemia) 
Immunization (rabbits) and 
serologya d: In vitro
immunochemical method or 
neutralization in cell cultures 
(specific details not provided 
in Ph. Eur. monograph) 
Rosskopf-Streicher et al. 
2004 [92]; Hendriksen et 
al. 1998 [90]; EDQM 
1997, 2007 [91]; Ph. Eur. 
Monograph 363 [76] 
Rabbit
immunization/mouse 
TNT
9 CFR 113.111 and 112; 
USDA SAM 201 (Type 
C, 2008) [61]; SAM 203 
(Type D, 2007) [62] 
Tetanus Antitoxin 
Products 
(equine); 
(Clostridium tetani)
Immunization (guinea pigs) 
and serologya,c: In vitro toxin-
binding inhibition (TOBI), 
indirect ELISAc
Hendriksen et al. 1994 
[93]; USDA SAM 217 
(2009) [72]; Ph. Eur. 
Monograph 697 [73]; 
Council of Europe (1996) 
[94] 
Guinea pig 
immunization/guinea pig 
toxin–antitoxin
neutralization test 
9 CFR 113.114; USDA 
SAM 206 (2007) [95] 
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Vaccine Product 
(Disease) 
3R Alternative References For Alternative Methods 
Traditional Test 
Procedure for Which 
the Alternative Method 
is Applicable 
References For 
Traditional Methods 
Leptospira interrogans
Serovar canicola
bacterin
Canine leptospiral 
(inactivated,
adjuvanted and non-
adjuvanted) 
Immunization (hamsters) and 
serologya e: in vitro method to 
determine antibodies 
(a validated serological 
method is permitted, no 
further details provided in the 
Ph. Eur.) 
Ph. Eur. Monograph 447 
[78]  
Immunization challenge 
test in hamstersf
9 CFR 113.103; USDA 
SAM 609 (2008) [68] 
Leptospira interrogans
Serovar hardjo bacterin 
E
Bovine Leptospira
hardjo
Immunization (guinea pigs) 
and serologya e: micro-
agglutination test 
Ph. Eur. Monograph 1939 
[79] 
Cattle immunization 
challengeg:
Immunization challenge 
test in hamsters 
9 CFR 113.105 [96] 
a Published in the European Pharmacopoeia.  
b Not for routine batch release (Ph. Eur.).  
c Accepted by U.S. regulatory authorities
d The European Pharmacopoeia states that following serology, an immunochemical method or neutralization in cell cultures is considered 
acceptable following product-specific validation.
e Applicable after in-house (product specific) validation.  
f The European Pharmacopoeia states endpoint is “signs” of the disease and not lethality.  
g The European Pharmacopoeia states that cattle are used for prelicensing while serology in guinea pigs is conducted for routine batch release 
testing.
Protective antigens and reference standards must be identified and characterized. In addition, antibodies and other 
reagents necessary to conduct the serological test must be available for use. This is also true for replacement of the 
TNT, where there is a need for improved specific cell lines to detect the enzymatic activity of toxins. As 
immunological research advances, it may be possible to incorporate new methodologies based on functionality of 
antibodies or other immune responses, including the use of macrophages and dendritic cell lines. 
Workshop participants recommended the following priority activities to advance the development and 
implementation of serological methods: 
x Studies and actions necessary for vaccine manufacturers to implement the use of the serological assay for rabies 
vaccines
x Research necessary to develop ELISAs or cell-based assays for Clostridium spp. vaccines that currently use in 
vivo TNTs 
x Development of serological methods for Leptospira spp. vaccines 
x Identification of protective antibodies for fish vaccines 
x Promotion of product-specific validation by manufacturers for available serological methods for those vaccines 
that currently use the challenge test 
6.2.1. Rabies vaccines  
Further development, validation, and implementation of serological tests for human and veterinary rabies 
vaccines were the highest priorities identified by workshop participants due to the large number of mice used in the 
test and the high variability of the current in vivo potency test (i.e., the mouse rabies challenge test). Over the past 10 
years, extensive research has been directed toward replacing the rabies challenge test with a serological method. 
However, there have been significant difficulties in correlating the serological test to the mouse challenge test due to 
variability in the challenge test [54, 55, 85, 98].  
Two serological methods have been developed for inactivated veterinary rabies vaccines: the rapid fluorescent 
focus inhibition test (RFFIT) [81, 84, 99] and the fluorescent antibody virus neutralization (FAVN) test [82]. A 
recent study demonstrated good correlation between results from the RFFIT and the challenge test [81]. In a 
validation study [80], the RFFIT was found to have good reproducibility within and between laboratories, thus 
providing a potential alternative to the mouse vaccination–challenge assay [22]. Considering these recent 
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developments, workshop participants recommended a focused international workshop to discuss the barriers and 
actions necessary to achieve international implementation of the RFFIT. Note: In January 2011, the European 
Pharmacopoeia published a draft monograph incorporating the RFFIT as a new alternative serological potency assay 
for inactivated veterinary rabies vaccines [85]. 
For human rabies vaccines, the in vivo potency release test is similar to that used for veterinary products. Potency 
is defined as the geometric mean of the results of two valid mouse potency challenge tests with humane endpoints 
[19, 50]. Although ELISA-based assays have replaced several animal-based immunogenicity assays for human 
vaccines, this is not yet true for human rabies vaccines. Although the neutralizing antigens for rabies are well 
defined, a clear correlation has not been demonstrated between the amount of antigen required to induce an immune 
response in animals, the amount of antigen measured using an in vitro assay, and the protective immune response in 
humans [19].  
While developing a single potency test (serological or antigen quantification) for both human and veterinary 
rabies vaccines would be ideal, it will be necessary to adapt any potency test for both product-specific and virus 
strain-specific vaccines [54]. Due to the clear overlap between human and veterinary rabies vaccines, workshop 
participants encouraged future collaboration between human and veterinary vaccine manufacturers and regulatory 
agencies during the development of alternatives for rabies vaccine potency testing.  
6.2.2. Clostridium spp. vaccines: replacing in vivo toxin neutralization tests 
Traditional potency testing for veterinary Clostridium spp. vaccines includes an in vivo rabbit immunization 
study followed by quantitative assessment of toxin-neutralizing antibodies in serum from the rabbits using a toxin 
neutralization test. While in vitro TNTs have been developed for some Clostridium spp. vaccines, many of these 
vaccines still require the use of mice to demonstrate toxin neutralization in vivo (e.g., C. novyi [63] and C.
perfringens [61] (Table 3)). The possibility of using in vitro TNTs to test Clostridium spp. vaccine potency is now 
supported by general guidance published for C. novyi [76], C. perfringens [74], and C. septicum [75] and by a 
validated ELISA to measure toxin neutralization for C. chauvoei [100, 101]. 
Global implementation is still needed for many serological methods that are now used only regionally for 
Clostridium spp. vaccines. This may require broader access to detailed test method protocols and increased 
availability of standard references and reagents from sources in the Europe (EDQM) and the United States (USDA). 
Based upon the current scientific literature and published regulatory methods, the replacement of the mouse TNT for 
other specific Clostridium spp. vaccines, as well as the global application of existing in vitro serological methods, 
appears achievable with appropriate development and validation efforts.  
Vaccine manufacturers are frustrated by the need to use different potency testing methods depending upon the 
location of vaccine usage and sale. Animal use (as well as time and costs) would be significantly lower if there were 
global application of existing or newly validated alternative methods, especially for the Clostridium spp. and rabies 
veterinary vaccines. 
6.2.3. Leptospira spp. vaccines (specifically Leptospira hardjo and Leptospira bratislava) 
The current in vivo Leptospira potency test consists of hamster vaccination followed by challenge ten days later. 
The time-intensive in vivo test takes more than five weeks to complete and exposes personnel to live Leptospira
bacteria serovars, many of which are zoonotic. The USDA recently developed an ELISA to compare the relative 
potency of specific bacterins to a qualified reference standard for L. interrogans serovars (pomona [102], canicola 
[103], grippotyphosa [104], and icterohaemorrhagiae [105]). Additional studies to be completed by the USDA 
include testing for interference by adjuvants and other vaccine components [17]. Therefore, in vivo vaccination–
challenge methods are still in use for many Leptospira spp. vaccines, including the following L. interrogans
serovars; pomona [67], canicola [68], grippotyphosa [70], and icterohaemorrhagiae [69]. Successful completion of 
these studies, along with product-specific validation, will be required to replace the vaccination–challenge test with 
the recently developed serological assays.
Both in vivo and in vitro methods are published in the relevant USDA SAMs and the European monographs (e.g., 
the canine leptospiral serology and antigen quantification method [78] and the bovine leptospiral serology method 
[79, 106, 107]. Vaccines for Leptospira hardjo and L. bratislava were also identified as candidates for conversion to 
serological methods due to progress made in research performed to date in addition to the extensive use of these 
vaccines.
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6.2.4. Fish vaccines 
This workshop emphasized the importance of fish vaccine potency tests because of the large number of fish used 
in vaccination–challenge procedures, including the large numbers of unvaccinated controls [14]. The majority of 
fish vaccine potency release tests consist of a host animal vaccination–challenge method; and little progress has 
been achieved in reducing, refining, or replacing the use of fish in this process [108]. Fish inactivated bacterial 
vaccines have been used successfully in aquaculture, but only recently have a significant number of effective viral 
vaccines for fish been developed [109]. Increasingly, adjuvants and immunostimulants are being used to enhance 
vaccine potency in fish, thereby further complicating the successful development of alternative fish vaccine potency 
tests [110]. For many fish vaccines, the correlation of serological response with protection has not been well 
established, thereby impeding the development of serological potency tests [108]. However, some protective 
antigens have been identified for inactivated bacterial vaccines such as those protecting from Vibrio salmonicida
and Vibrio anguillarum diseases, suggesting that serology or antigen quantification methods could be developed for 
selected vaccines [108]. Workshop participants agreed that the following are needed: (1) further research to identify 
the antibodies involved in protective immunity, (2) development of the assays and reagents to measure these 
antibodies, and (3) validation of the antibody assays used in serological assessment of protective immunity. 
Expanded research and development efforts are expected as additional fish vaccines enter the market and more 
animal health companies develop vaccines for aquaculture use. 
7. Veterinary vaccine potency testing: strategies to reduce animal use 
7.1. State of the science 
Reducing the number of animals used in challenge and serological assays is considered a high priority for all 
regulatory agencies, vaccine manufacturers, and other interested stakeholders. The number of animals used per test 
has been reduced over time as improvements have decreased variability in assays, which can lead to using fewer 
animals to achieve the same statistical power [107, 111, 112].  
In addition, where it can be scientifically justified, limiting the number of dose groups can reduce the number of 
animals used. For example, single-dose potency testing can be used in place of multidose testing for inactivated 
veterinary rabies vaccines under certain testing circumstances [48] (Table 4). However, a single-dose potency test 
only shows that the vaccine under test meets the minimum requirement for potency. It is not a quantitative estimate 
of potency [19, 46]. A single-dilution test is best used when production is consistent, quality control systems are 
excellent, and the amount of the test serial antigen is well over the minimum qualified standard. For a multidilution 
test, the test response curve is compared to a standard curve, and the median effective dose is determined by relative 
potency. For human rabies vaccines, a multidose approach uses approximately 200 mice per test, compared to 60 
mice per test in the single-dilution test [19].  
Another reduction alternative is using fewer animals per group in multidilution tests. For example, a recent report 
indicated that statistically valid assays could be obtained using the mouse rabies challenge test when 9 mice instead 
of 18 were used for each dose for potency assessment of human rabies vaccine [113].  
Table 4. Veterinary vaccine potency assays that incorporate reduction alternative methods 
Vaccine Product 
(Disease) 
3R Alternative References
Traditional Test 
Procedure for Which 
the Alternative 
Method is applicable 
Rabies vaccine 
(Lyssavirus rabies)
Single-dilution assaya Bruckner et al. 2003 [54]; 9 CFR 
113.209 [47]; de Moura et al. 
2009 [113]; 
Ph. Eur. Monograph 451 [48] 
Multiple-dilution assays
a Published in the European Pharmacopoeia.  
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Another example of reducing animal use for testing of a biological product is the modified tuberculin-PPD test 
recently published by the World Organization for Animal Health (OIE) [26, 114]. Employing an experimental 
design different from that of the current standard test, the modified test involves the injection of each guinea pig 
with test and reference serials, thus allowing each animal to act as its own control. The modified test, which 
decreases the number of animals used by more than 50%, reduces the amount of individual animal variability while 
maintaining statistical power [26, 114]. 
7.2. Knowledge gaps and priority research, development, and validation activities 
Workshop participants agreed that further reduction of animal numbers required for vaccination–challenge and 
serological tests will require better understanding of the causes of variability and the basis for incomplete or 
inconclusive results that necessitate repeat testing. In addition, for many in vivo potency tests, the number of 
unvaccinated controls may be reduced, thereby reducing the number of animals experiencing pain and distress. 
Significant reduction can be achieved in fish vaccines, which can use 50 to 100 control animals per test. 
The recommended approaches to potential reduction of group sizes involves a systematic investigation into the 
causes of excessive variation and repeat testing, followed by a sustained effort to reduce or eliminate the sources 
contributing to variation and incomplete test results. As the factors affecting experimental variability are reduced or 
eliminated, the minimum number of animals required to maintain the necessary statistical power should be 
reassessed.
To reduce the number of control animals used in vaccination–challenge potency tests, archival control data 
should be reviewed to determine if control size might be reduced while maintaining statistical power. Workshop 
participants agreed that flexibility should be incorporated into the regulatory process so that the reduction of animals 
can be applied on a case-by-case basis, especially for minor-use situations.  
Additionally, increased emphasis should be placed on evaluating the use of single-dilution assays to replace 
multidilution methods for both vaccination–challenge and serology assays. This again would require a retrospective 
review of existing data as well as more-detailed procedures and technical training to ensure valid test results. As 
discussed earlier, the current in vivo potency test for inactivated veterinary rabies vaccine is a multidilution 
vaccination–challenge test in mice (NIH test) known to be highly variable with a high frequency of invalid results 
[55, 115, 116]. Reduction variations include the use of a single-dilution vaccination regimen [48] or a reduction in 
the number of animals used per dilution [113].  Regulatory authorities and vaccine companies should assess whether 
these reduction variations will meet their specific needs for potency testing and individual vaccine product release. 
8. Reduction and refinement: potential application of human vaccine potency testing alternatives to 
veterinary vaccines
There are three general areas in which the application of recent progress with human vaccine reduction and 
refinement alternatives might be applied to veterinary vaccines and vice versa. First, knowledge could be shared by 
researchers and vaccine manufacturers for human and veterinary zoonotic vaccines in which the mechanism of 
pathogenesis is similar across species. For example, synergy between experts in human and veterinary tetanus 
vaccines could facilitate and expedite the development of an alternative potency test for both human and veterinary 
tetanus vaccines. One successful crossover is potency testing of human and veterinary vaccines, which involves 
vaccinating guinea pigs and then quantifying anti-tetanus toxoid antibodies in serum by indirect ELISA [72] or by a 
ToBI test [73, 93]. Workshop participants encouraged a collaborative effort between human and veterinary tetanus 
vaccine experts to expedite global implementation and use of the serological methods to further refine animal use.  
As previously discussed, further development, validation, and implementation of a serological test for both 
human and veterinary rabies vaccines is a high priority due to the variability of the in vivo potency test and the large 
numbers of mice used in the mouse challenge test. Workshop participants recommended formation of a working 
group of experts in both human and veterinary rabies vaccines to focus on such efforts. 
Secondly, interaction was also proposed between human and veterinary vaccine experts to share knowledge of 
human pathogens that have genetic, phenotypic, and structural characteristics similar to those of animal pathogens 
(e.g., Bordetella pertussis [whooping cough] in humans and Bordetella bronchiseptica [kennel cough] in dogs). This 
knowledge exchange could provide valuable insights to support advancement of alternative potency testing methods. 
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Finally, the workshop participants encouraged human disease vaccine specialists to share information on how 
master references or standard references for vaccines are used, validated, stored, dated, qualified, requalified, and 
monitored. This information should include policies and procedures for distribution and cost sharing. Reference 
monitoring requirements are extensive and difficult to meet, thereby delaying in vitro test method development. 
Therefore, increased interaction between human and veterinary vaccine experts may be valuable. Workshop 
participants also suggested further discussion among regulatory authorities of ways to identify and simplify 
requirements for extension of stability and shelf life of references. They also recommended increased cooperation 
between human and veterinary vaccine stakeholders to produce, organize, monitor, and supply references and 
reagents in order to facilitate the development of alternative potency tests. 
9. Achieving broader acceptance and use of currently available reduction and refinement methods for 
potency testing of veterinary vaccines 
Workshop participants concluded that broader acceptance and use of reduction and refinement methods could 
result from improved information disseminated in global regulatory guidance documents to multiple stakeholder 
groups, countries, and regions. Such efforts should include (1) agreement on potency testing among national and 
international regulatory authorities and organizations and (2) continued harmonization efforts to avoid multiple 
potency testing of the same serial marketed in different countries. In addition, general principles and procedures for 
the validation of alternative vaccine test methods should be standardized and harmonized internationally, including 
those necessary to define humane endpoints.  
As a starting point, workshop participants recommended that regulatory agencies harmonize the general 
principles for validation of alternative potency tests. For example, the U.S. Animal and Plant Health Inspection 
Service (APHIS) CVB has issued general guidelines for the validation of (1) in vitro potency assays [117] and 
(2) relative potency assays and reference preparations based on ELISA antigen quantification [97]. Guidance 
documents are needed to support the refinement of animal use, especially for serological ELISAs for Clostridium 
spp. vaccines.
Workshop participants recognized that international organizations can serve an important role in achieving global 
harmonization and implementation of alternative methods. For example, the International Cooperation on 
Harmonisation of Technical Requirements for Registration of Veterinary Products (VICH) is a trilateral program of 
collaboration among the regulatory authorities and animal health industries of the European Union, Japan, and the 
United States. The VICH aims to harmonize technical requirements for registration of veterinary medicinal products 
by establishing and implementing specific guidelines after extensive input and review from national regulatory 
authorities. 
The VICH was established under the auspices of the World Organisation for Animal Health (OIE), which 
participates as an associate member in the VICH process by supporting and disseminating the outcomes at the 
worldwide level (http://www.vichsec.org/). Because VICH guidelines are developed by the international scientific 
community, there is broad-based review and acceptance, which should expedite implementation. Examples of VICH 
guidelines include VICH guidelines GL 41: Examination of Live Veterinary Vaccines in Target Animals for 
Absence of Reversion to Virulence [118] (adopted by the U.S. in 2008) and GL 44: Target Animal Safety for 
Veterinary Live and Inactivated Vaccines [119] (adopted by the U.S. in 2010). In addition, a draft guideline is in 
development to harmonize data requirements for waiving the target animal batch safety test for inactivated 
veterinary vaccines [26]. 
Harmonizing testing procedures for individual vaccines and ensuring ready availability of necessary reagents on 
a global basis would help support the wider use of alternative methods for vaccine testing. Organizations such the 
USDA (CVB and APHIS) and the Biological Standardisation Programme (BSP) under the EDQM develop, produce, 
characterize, and distribute selected references and reagents. These references and reagents are available to 
manufacturers for their use in developing assays; for direct or relative potency comparisons; or for independent 
efficacy, identity, and purity testing. 
The availability of reference standards is a key factor in the ability of vaccine manufacturers to transition to an 
alternative potency assay. As the master reference is correlated to host immunogenicity, its relative stability must be 
monitored over time to assure that the reference remains stable during storage. For example, in the United States, a 
frozen master reference is allowed a maximum dating of five years or, if stored under refrigeration, a maximum 
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dating of two years [97]. After the dating period, each reference must be requalified in the host animal 
immunogenicity test. To reduce, refine, and replace the use of animals for requalification, workshop participants 
recommended that requalification should be conducted in any currently acceptable potency test.
Development of new requalification tests for reference standards is the responsibility of vaccine manufacturers. 
However, this can require significant resources, and vaccine manufacturers are less likely to commit resources to 
products that are older and less profitable. Therefore, the ready availability of reference standards that are 
requalified using new alternative tests could accelerate reduction, refinement, and replacement. Workshop 
participants emphasized that broad international availability of reference standards supported by regional and 
international authorities would be ideal and that universal reference standards could be monitored and maintained by 
organizations such as the OIE, USDA, WHO (World Health Organization), or EDQM.  
10. Discussion 
This was the first international workshop in the United States to focus on the reduction, refinement, and 
replacement of animal use for potency and safety testing for human and veterinary vaccines. A key aspect of the 
workshop was bringing together experts from industry, academia, and government in the areas of potency and safety 
testing for both human and animal vaccines. The commonalities in testing objectives and challenges, together with 
the exchange of knowledge and experience between scientists working in either human or animal vaccines, provided 
an obvious strategic synergy during the discussions.  
International participation in the workshop also contributed to improved sharing of scientific and regulatory 
perspectives, ideas, and progress from many different countries and regions. Despite different approaches, 
terminology, and processes, all stakeholders have the same goal regardless of their geographic location: to produce 
and ensure safe and effective vaccine products for people and animals. There was also a unified commitment from 
industry participants, government officials, and all other stakeholders to encourage and support potency and safety 
testing methods that reduce or avoid the need for animals and to provide for the most humane use of animals where 
they must still be used.  
Plenary session presentations and subsequent breakout groups allowed participants to clarify the current status of 
alternative methods for vaccine potency and safety testing and to discuss and identify priorities for future efforts to 
reduce, refine, and replace animal use for vaccine potency testing. While the ultimate goal is to avoid the need to use 
animals for vaccine potency and safety testing, for many vaccines this will require significant research, 
development, and validation efforts. This session, therefore, focused on identifying priorities and ways to both 
further reduce pain and distress and reduce the number of animals required for individual tests for studies that still 
require the use of animals.  
Workshop participants agreed that every effort should be made to minimize or avoid pain and distress. They 
agreed that death is not a scientifically required endpoint for veterinary vaccine potency testing and that euthanasia 
of moribund animals should always be incorporated in test procedures. More importantly, workshop participants 
recognized that earlier humane endpoints have now been developed and validated for several vaccination–challenge 
procedures. Accordingly, workshop participants identified as an urgent priority the identification and 
implementation of earlier, more humane endpoints for all other challenge tests, as well as for in vivo TNTs. The 
systematic collection and identification of potential clinical signs and other objective parameters predictive of 
eventual moribund condition, or other earlier indicators of the lack of vaccine protection can accomplish this. To 
minimize or avoid spontaneous deaths, the effective implementation of humane endpoints may require monitoring 
more frequently.  
Serological potency methods that quantify protective antibodies in vaccinated animals can avoid the significant 
pain and distress involved in vaccination–challenge procedures. Serological methods are currently used for several 
potency tests, including those for tetanus, erysipelas, and some clostridial diseases. However, there are still regional 
differences in the availability and implementation of some assays. Increased availability of reagents and availability 
of validation study results would likely aid in broader use of such methods.  
Workshop participants identified alternative methods for potency testing of rabies vaccines as one of the highest 
priorities for further efforts to develop, validate, and implement alternative methods. The recent development and 
validation of a serological test for veterinary rabies vaccines were highlighted. Workshop participants recommended 
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that a workshop should be convened to focus on advancing and implementing vaccine serological and antigen 
quantification methods for both human and veterinary rabies vaccines.
Workshop participants recognized that in vitro serological test methods have been developed for many 
Clostridium spp. and some Leptospiral spp. vaccines and recommended extension of this technology to other related 
vaccines. Workshop participants recommended increased involvement and participation by vaccine manufacturers in 
efforts to identify how to expand the use of such methods in order to further reduce and refine animal use.  
 Workshop participants identified control groups in challenge tests as an immediate priority target for both 
reduction and refinement strategies. Retrospective reviews of archival clinical data could identify earlier humane 
endpoints specific to the infected controls and also gauge the potential for reducing the number of control animals 
necessary to maintain statistical significance.  
Continued basic and applied research is critical to better understanding of how more-complex vaccines confer 
immunity. This applies especially to vaccines that may confer immunity through both humoral antibody and cell-
mediated responses. Additional basic research will be needed to address fish vaccines potency determinants and to 
generate a better understanding of how these vaccines confer protection. This is important as aquaculture vaccines 
are becoming more widely used with the growing global implementation of fish farming. Workshop participants 
noted that further research is needed to identify and understand the role of antibodies in fish protective immunity 
and to develop assays and reagents to measure these antibodies in order to support serological assessment of 
protective immunity. Additional research is also needed to develop cell-based or other in vitro methods that can 
replace in vivo TNTs.
Workshop participants identified some serological vaccine potency tests that have been adopted in some regions 
of the world but that are not yet universally implemented. Participants recommended that international 
harmonization and greater global availability of reagents could facilitate increased use.  
Workshop participants recommended development of global regulatory guidance documents to gain broader 
acceptance and use of alternative testing methods. This should include international agreement on a high-level 
roadmap and continued harmonization efforts to avoid multiple potency testing on the same serial marketed in 
different countries. General principals and procedures for validation of alternative vaccine test methods should be 
standardized and harmonized internationally.  
Lastly, there is a critical need for the development and broad availability of reagents and reference standards such 
as antibodies, viruses, bacteria, and antigens to accelerate transition to reduction and refinement testing. The 
availability of reference standards is a key factor in the ability of vaccine manufacturers to switch to an alternative 
potency assay.
11. Conclusions 
This workshop session provided a comprehensive review of the state of the science and availability of alternative 
methods that can further reduce and refine animal use for veterinary vaccine potency testing where animals must 
still be used. Participants identified critical research and development needs and priorities to further advance and 
implement reduction and refinement methods, and identified potency testing that should have the highest priority for 
reduction and refinement efforts. 
 Implementation of earlier human endpoints, in vitro serological methods, in vitro TNTs, and various reduction 
strategies identified at this workshop can be expected to have a significant near-term impact on improving the 
welfare of animals and reducing animal use for vaccine potency testing. Furthermore, increased targeted efforts to 
conduct the recommended high priority research and development activities can also be expected to have a similar 
impact. To facilitate future progress, this workshop set the stage for a series of future workshops that will focus on 
alternatives for specific priority vaccines. This and future workshops are expected to help achieve international 
regulatory consensus on test methods and practical implementation of scientifically sound and valid alternative 
methods.  
International experts and leaders from industry, government, academia, and other stakeholder groups participated 
enthusiastically in this workshop, and provided evidence of a strong global commitment to reducing, refining, and 
replacing animals in veterinary vaccine potency testing. Continued cooperation and collaboration will undoubtedly 
accelerate development and use of alternative methods. Finally, implementation of the workshop recommendations 
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can be expected to advance alternative methods for vaccine potency testing that will not only benefit animal welfare 
and reduce animal use but also support the continued protection of people and animals.  
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